GSK PLC 2003 SR
The report highlights GSK's corporate responsibility activities in 2003, focusing on medicines for the developing world, community investment, and environmental performance. Key achievements include donating 94 million albendazole treatments for lymphatic filariasis and reducing greenhouse gas emissions per unit sales by 8%. The company formally adopted ten Corporate Responsibility Principles and expanded its preferential pricing for HIV/AIDS medicines. Additionally, GSK invested £338 million in community programs and reported that 34% of its management positions are held by women.
Company: GSK PLC
Sector: Manufacturing
Country: United Kingdom
Year: 2003
Type: SR
Pages: 36
Back to company
GSK PLC
Corporate Responsibility Report
The report highlights GSK's corporate responsibility activities in 2003, focusing on medicines for the developing world, community investment, and environmental performance. Key achievements include donating 94 million albendazole treatments for lymphatic filariasis and reducing greenhouse gas emissions per unit sales by 8%. The company formally adopted ten Corporate Responsibility Principles and expanded its preferential pricing for HIV/AIDS medicines. Additionally, GSK invested £338 million in community programs and reported that 34% of its management positions are held by women.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2003
Reporting Period
Jan 1, 2003 - Dec 31, 2003
Fiscal Year
2003
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Energy Consumption
Water Consumption
Women in Management
Workplace Fatalities
Employees